<unk>  (trade name Lyxumia in the European Union and Adlyxin in the U.S. and manufactured by Sanofi) is a once-daily injectable GLP-1 receptor agonist for the treatment of type 2 diabetes.
Lixisenatide
Linaclotide
Pramlintide
Tirzepatide
Glibenclamide
Canagliflozin
Linagliptin
Eluxadoline